BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has received an average rating of “Hold” from the eleven ratings firms that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $8.83.
Several equities research analysts recently commented on the stock. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, January 23rd. ValuEngine lowered shares of BioCryst Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, February 14th. Barclays assumed coverage on shares of BioCryst Pharmaceuticals in a research note on Wednesday, December 20th. They set an “equal weight” rating and a $6.00 price objective on the stock. Royal Bank of Canada raised shares of BioCryst Pharmaceuticals from a “sector perform” rating to an “outperform” rating and set a $6.00 price objective on the stock in a research note on Tuesday, January 2nd. Finally, BidaskClub raised shares of BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, February 8th.
BioCryst Pharmaceuticals (BCRX) traded up $0.22 during trading hours on Friday, reaching $5.02. 870,553 shares of the company traded hands, compared to its average volume of 1,335,476. BioCryst Pharmaceuticals has a 1-year low of $3.95 and a 1-year high of $9.25. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.53 and a quick ratio of 2.53. The company has a market capitalization of $472.48, a price-to-earnings ratio of -7.84 and a beta of 2.81.
A number of large investors have recently bought and sold shares of the stock. Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of BioCryst Pharmaceuticals in the third quarter worth approximately $132,000. Trustcore Financial Services LLC bought a new position in shares of BioCryst Pharmaceuticals in the fourth quarter worth approximately $126,000. SG Americas Securities LLC lifted its stake in shares of BioCryst Pharmaceuticals by 98.6% in the third quarter. SG Americas Securities LLC now owns 26,990 shares of the biotechnology company’s stock worth $141,000 after buying an additional 13,402 shares in the last quarter. Jane Street Group LLC bought a new position in shares of BioCryst Pharmaceuticals in the fourth quarter worth approximately $135,000. Finally, Teacher Retirement System of Texas bought a new position in shares of BioCryst Pharmaceuticals in the fourth quarter worth approximately $155,000. 86.79% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “BioCryst Pharmaceuticals, Inc. (BCRX) Receives Average Rating of “Hold” from Brokerages” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/24/biocryst-pharmaceuticals-inc-bcrx-receives-average-rating-of-hold-from-brokerages.html.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.